Monday, March 17, 2025 | 10:25 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Race for coronavirus cure hits reality as clinic complications mount

Regulators and drugmakers have faced questions about whether political pressure was overwhelming scientific rigor ahead of the presidential election on Nov. 3

covid, coronavirus, vaccine, drug, pharma
Premium

Lilly’s drug is part of a promising class of therapies known as monoclonal antibodies, which top U.S. infectious-disease expert Anthony Fauci has called a bridge to a vaccine.

Riley Griffin and Michelle Fay Cortez | Bloomberg
The sprint to find medical breakthroughs to contain Covid-19 stumbled this week, as a pair of pharmaceutical giants working to develop treatments and vaccines suffered setbacks in the clinic.

On Tuesday, Eli Lilly & Co. said that enrollment in a government-sponsored clinical trial of its antibody therapy had been paused out of safety concerns. That came less than 24 hours after Johnson & Johnson said research on its experimental vaccine was paused after a study volunteer fell ill.

The developments are likely to heighten worry that the pursuit of products to prevent and treat infections is moving too quickly. Regulators and drugmakers

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in